HOWL · Werewolf Therapeutics, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“We believe there is substantial doubt about our ability to continue as a going concern for at least twelve months from the date that these condensed consolidated financial statements are issued in this Quarterly Report. We are currently evaluating strategies to raise additional capital, however, there can be no assurances that we will be successful in mitigating the conditions which raise substantial doubt about our ability to continue as a going concern in the near term, if at all.”View the 10-Q filed Jul 31, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $32.91M | $44.83M | $56.43M | $41.78M | $53.76M | $35.27M | $16.64M | |
| $19.35M | $15.85M | $19.05M | $18.67M | $18.7M | $14.82M | $5.76M | |
| $52.26M | $60.68M | $75.48M | $60.45M | $72.46M | $50.09M | $22.4M | |
| -$31.26M | -$60.68M | -$73.59M | -$40.5M | -$56.06M | -$50.09M | -$22.4M | |
| $4.55M | $5.27M | $4.66M | $3.14M | $0 | — | — | |
| $1.97M | $3.11M | $6.67M | $7.42M | $1.91M | — | — | |
| -$3.36M | -$145K | $3.08M | $3.14M | $2.25M | $104K | $7.36M | |
| — | $0 | — | — | — | — | — | |
| -$34.61M | -$60.82M | -$70.52M | -$37.37M | -$53.81M | -$49.98M | -$15.04M | |
| -$56.27M | -$60.82M | -$70.52M | -$37.37M | -$53.81M | -$201.93M | -$28.22M | |
| USD/shares | -$0.72 | -$1.32 | -$1.63 | -$1.05 | -$1.86 | -$10.94 | -$28.08 |
| USD/shares | -$0.73 | -$1.33 | -$1.63 | -$1.05 | -$1.86 | -$10.94 | -$28.08 |
| shares | — | 46.02M | 43.33M | 35.65M | 28.86M | 18.46M | 1.01M |
| shares | — | 46.81M | 43.86M | 35.65M | 28.86M | 18.46M | 1.01M |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 0 | 10-Q filed 2026-07-31 |
| Current portion of notes payable | 2026-06-30 | USD 0 | 10-Q filed 2026-07-31 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 0 | 10-Q filed 2026-07-31 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 285 similar-size Biotechnology companies (of 532 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $0 | $1,885,000 | $19,943,000 |